Volume 3, Issue 4, July 2017, Page: 48-51
Limited Management of Systemic Erythematosus Lupus in Madagascar
Fandresena Arilala Sendrasoa, Department of Dermatology, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar
Irina Mamisoa Ranaivo, Department of Dermatology, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar
Naina Harinjara Razanakoto, Department of Dermatology, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar
Malalaniaina Andrianarison, Department of Dermatology, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar
Onivola Raharolahy, Department of Dermatology, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar
Lala Soavina Ramarozatovo, Department of Dermatology, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar
Fahafahantsoa Rapelanoro Rabenja, Department of Dermatology, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar
Received: Oct. 31, 2016;       Accepted: Dec. 27, 2016;       Published: Oct. 24, 2017
DOI: 10.11648/j.ijbecs.20170304.14      View  2041      Downloads  83
Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that involves multiple organs and has alternating periods of flare-ups and quiescence. SLE requires multiple paraclinical and therapeutic investigations that are not accessible by Malagasy patients. We aim to assess the monthly direct cost in SLE referring to international recommendations. The cost of paraclinical exams and treatment expenses were estimated as a percentage of the MMMS (Malagasy Minimum Monthly Salary). According to international recommendations, the cost of first-line paraclinical exams for SLE diagnosis was 274,2% of the MMMS. The costs of diagnostic tests were 110,9% and 923,4% of the MMMS to research renal and neurological damage, respectively. The monthly cost of pharmacological therapies ranged from 132,2% to 205,9% of the MMMS, depending on the severity of SLE. Clinical examination and affordable paraclinical exams were fundamental in our practice to manage systemic lupus erythematosus lupus. Appropriate recommendations for emergent countries should be come up.
Keywords
Systemic Lupus Erythematosus, Cost, International Recommendations
To cite this article
Fandresena Arilala Sendrasoa, Irina Mamisoa Ranaivo, Naina Harinjara Razanakoto, Malalaniaina Andrianarison, Onivola Raharolahy, Lala Soavina Ramarozatovo, Fahafahantsoa Rapelanoro Rabenja, Limited Management of Systemic Erythematosus Lupus in Madagascar, International Journal of Biomedical Engineering and Clinical Science. Vol. 3, No. 4, 2017, pp. 48-51. doi: 10.11648/j.ijbecs.20170304.14
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Doria A, Zen M, Canova M, Bettio S, Bassi N, Nalotto L et al. SLE diagnosis and treatment: when early is early. Autoimmun Rev 2010; 10 (1): 55-60.
[2]
Zhu TY, Tam LS, Li EK. The socioeconomic burden of systemic lupus erythematosus: state-of-the-art and prospects. Pharmacoeconomic Outcomes Res 2012; 12: 53-69.
[3]
Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1000 patients. Medicine (Baltimore) 2003; 82: 299-308.
[4]
Lau CS, Mak A. The socieconomic burden of SLE. Nat Rev Rheumatol 2009; 5: 400-404.
[5]
Bertrias G, Ioannidis J. P, Boletis J, Bombardieri S, Cervera R, Dostal C et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67: 195-205.
[6]
Mosca M, Tani C, Aringer M, Bombardieri s, Boumpas D, Brey R et al. EULAR recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010; 69 (7): 1269-74.
[7]
Clarke AE, Panopalis P, Petri M, Manzi S, Isenberg DA, Gordon C et al. SLE patients with renal damage incur higher health care costs. Rheumatology 2008; 47: 329-33.
[8]
Zhu TY, Tam LS, Lee VW, Lee KK, Li EK. The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1159-67.
[9]
Petri M, Orbai A. M, Alarcon G. S, Gordon C, Merrill J. T, Fortin P. R et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthr Rheum 2012; 64 (8): 2677-86.
[10]
Sendrasoa F. A. Comparative analysis of acute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus. Madagascar: DEFS Memories, 2015; N°307.
[11]
Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus. Arthritis Care Res 2011; 63 (11): doi: 10.1002/acr. 20572.
[12]
Hahn B. H, McMahon M. A, Wilkinson A, Wallace W. D, Daikh D. I, Fitzgerals J. D et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012; 64 (6): 797-808.
[13]
Wilson EC, Jayne DR, Dellow E, Fordham RJ. The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis. Rheumatology 2007; 46 (7): 1096-101.
[14]
Aghdassi E, Zhang W, St-Pierre Y, Clarke AE, Morrison S, Peeva V et al. Healthcare cost and loss of productivity in a Canadian population of patients with and without lupus nephritis. J Rheumatol 2011; 38 (4): 658-66.
[15]
Zhu TY, Tam LS, Lee VW, Lee KK, Li EK. Systemic lupus erythematosus with neuropsychiatric manifestations incurs high direct costs: a cost-of-illness study in Hong Kong. Rheumatology 2009; 48 (5): 564-8.
Browse journals by subject